Madrigal reports Q4 2023 cash of $634M, appoints new CFO, resmetirom PDUFA March 14

MADRIGAL PHARMACEUTICALS, INC.

Appointed Mardi C. Dier as CFO; previously CFO at Portola, Ultragenyx, and Acelyrin.
Resmetirom PDUFA date March 14, 2024; company anticipates first NASH approval.
Cash and marketable securities $634.1M at Dec 31, 2023, up from $358.8M at Dec 31, 2022.
Operating expenses Q4 2023 $117.2M vs $85.3M YoY; full year $380.5M vs $293.6M.
G&A expenses Q4 2023 $46.5M vs $14.6M YoY due to commercial launch preparation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.